 |
|
|
| |
Lenacapavir Oral Bridging (300 mg QW) Maintains Efficacy with a Similar Safety Profile When SC LEN Cannot Be Administered
|
| |
| |
IAS 2023 july 25
Onyema Ogbuagu1, Anchalee Avihingsanon2, Sorana Segal-Maurer3, Hui Wang4, Martin S Rhee4, Hadas Dvory-Sobol4, Peter Sklar4, Jean-Michel Molina*5
|
| |
|
|
|
|
|
